| Cancer Immunotherapy Using NKG2D and DNAM-1 Systems. | |
| | |
MedLine Citation:
|
PMID: 22641658 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Although tumor antigen-specific immunotherapy, such as dendritic cell vaccine, has recently emerged as a promising clinical approach, one limitation of tumor antigen- and T-cell receptor (TcR)-specific immunotherapy is antigen-specific inhibition by antigen-specific regulatory T-cell and myeloid suppressor cells. Therefore, immunotherapy using a TcR-independent mechanism may be an alternative immunotherapeutic strategy. NKG2D (natural killer, group 2, member D) and DNAX accessory molecule-1 (DNAM-1) are both activated receptors that are strongly expressed on T-cells, γδT-cells, and NK cells. Therefore, the expression of ligands for NKG2D and DNAM-1 on tumor cells plays an important role in tumor opsonization by immune effector cell targeting. Various modulatory methods for up-regulating NKG2D and DNAM-1-ligands have been reported, and included chemotherapeutic agents and hyperthermia. Although there are many obstacles to the utilization of NKG2D and DNAM-1 for cancer therapy, combined treatments using immune cell therapy and chemotherapy that take advantage of NKG2D and DNAM-1 may be an ideal approach. |
| | |
Authors:
|
Takashi Morisaki; Hideya Onishi; Mitsuo Katano |
Related Documents
:
|
22383798 - Galectin-1 inhibits the viability, proliferation, and th1 cytokine production of nonmal... 22890838 - High-resolution genomic profiling reveals clonal evolution and competition in gastroint... 22321108 - Regulation of mast cell responses in health and disease. 22676448 - Cryopreservation of cell/scaffold tissue engineered constructs. 21219478 - Sonic hedgehog (shh)-gli signaling controls neural progenitor cell division in the deve... 7931828 - Primary cutaneous t-cell lymphoma: clinicopathological features and prognostic paramete... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anticancer research Volume: 32 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 2241-7 Citation Subset: IM |
Affiliation:
|
Fukuoka General Cancer Clinic, 3-1-1 Sumiyoshi, Hakata-ku, Fukuoka 812-0018, Japan. tmorisaki@cancer-clinic.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Boron tracedrugs challenge for neutron dynamic therapy.
Next Document: Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells ...